Prothena Corporation plc
PRTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$462.8M
Close$
$3.75
55.8% downside
Current Fair Value
55.8% downsideOvervalued by 55.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $462.80 Million |
|---|---|
| Enterprise Value | $182.22 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.53 |
| Beta | -0.33 |
| Outstanding Shares | 52,145,000 |
Return
| Return on Equity | -15.33% |
|---|---|
| Return on Assets | -14.54% |
| Return on Invested Capital | -18.21% |
Valuation & Multiples
| P/E Ratio | -10.65 |
|---|---|
| PEG | 12.5 |
| Price to Sales | 8.5 |
| Price to Book Ratio | 1.7 |
| Enterprise Value to Revenue | 3.34 |
| Enterprise Value to EBIT | -3.44 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$421,667
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$9.59 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 32.33% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 91.29% |
|---|---|
| Total Invested | $90,060▼ 99.98% |
| Investors Holding | 4▼ 193.00% |
ESG Score
No data
About Prothena Corporation plc
7 employees
CEO: Gene Kinney Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...